Mivacron (Mivacurium Chloride)

Mivacron, a non‑depolarizing neuromuscular blocker, is used in clinical settings that require rapid and reversible muscle relaxation.

• Facilitation of endotracheal intubation: Provides rapid onset muscle relaxation to enable safe airway management.
• Muscle relaxation during surgery: Maintains a controlled neuromuscular block throughout operative procedures.
• Adjunct to anesthesia: Enhances the overall anesthetic plan by allowing lower doses of other agents.

• Mivacurium chloride acts as a competitive antagonist at nicotinic acetylcholine receptors located on the motor end‑plate of the neuromuscular junction. By blocking acetylcholine binding, it prevents depolarization of the muscle fiber membrane, thereby inhibiting transmission of the nerve impulse and producing a dose‑dependent, reversible skeletal muscle relaxation.

Mivacron may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Transient flushing: Brief reddening of the skin, often self‑limiting.
• Mild hypotension: Slight drop in blood pressure that usually resolves without intervention.
• Tachycardia: Increased heart rate observed during induction.
• Bronchospasm: Temporary narrowing of the airways, more common in reactive airway disease.
• Nausea: Mild gastrointestinal discomfort post‑administration.

Serious or Rare Side Effects

• Anaphylaxis: Severe allergic reaction requiring immediate emergency treatment.
• Prolonged neuromuscular blockade: Extended muscle weakness beyond the expected duration.
• Respiratory depression: Inadequate ventilation requiring assisted breathing.
• Cardiac arrest: Rare but life‑threatening cardiac event.
• Malignant hyperthermia trigger: Potential precipitant in susceptible individuals.

When using Mivacron, clinicians should observe specific safety measures.

• Assess neuromuscular function: Continuously monitor depth of block with peripheral nerve stimulators.
• Evaluate pseudocholinesterase activity: Identify patients with genetic deficiency that may prolong effect.
• Review concomitant medications: Avoid agents that may potentiate neuromuscular blockade.
• Monitor cardiovascular status: Observe for hypotension or arrhythmias during infusion.
• Prepare for emergency reversal: Have anticholinesterase agents and resuscitation equipment readily available.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid)

• Pseudocholinesterase inhibitors (e.g., echothiophate, pyridostigmine): May markedly prolong neuromuscular blockade.
• Other neuromuscular blocking agents: Additive effects can lead to excessive paralysis.

Moderate Interactions (Monitor Closely)

• Aminoglycoside antibiotics: Potentiate blockade, requiring dose adjustment.
• Magnesium sulfate: Enhances neuromuscular inhibition, especially in obstetric patients.
• Inhalational anesthetics (e.g., sevoflurane): May increase the duration of muscle relaxation.
• Calcium channel blockers: Can modestly augment blockade.
• Anticholinesterase reversal agents: May shorten duration but require careful titration.